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Introduction: The gold standard treatment for Epidermal Growth Factor Receptor (EGFR) positive Non-Small Cell 
Lung Cancer (NSCLC)patients is represented byosimertinib, an irreversible third-generation EGFR inhibitor that has 
been providingimportant outcomes’ improvementscompared to chemotherapy and other target therapies; either 
upfront or as second line therapy, in case of  EGFR T790M detection after previous tyrosine kinase inhibitors 
(TKI).Osimertinib is generally well tolerated. Most common side effects are diarrhea, rash, paronychia, dry skin and 
alsochanges in QT interval.  
Presentation of case series: Here we report five cases of left ventricular dysfunction duringosimertinib treatment, 
observed between January 2017 and August 2018. The five patients, with a general low cardiovascular risk profile, 
required a dose modification/discontinuation of the TKI therapy and a specific cardio-protective treatment, normally 
with a recovery of the systolic function. 
Conclusion: Both American and European compound labels highlight warnings of cardiomyopathy and changes in 
cardiac contractility during osimertinib treatment, recommending cardiac monitoring and dose adjustment in patients 
with cardiac risk factors. In spite of this, a standardized echocardiographic follow-up in the entire population is still 
not available and recommendations about the use of tissue Doppler echocardiography with more sophisticated 
indices are missing. With the expanding use of osimertinib we need better strategies to prevent or mitigate 
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Treatment strategies for advanced NSCLC patients have rapidly evolved in recent years. Tumor 
molecular profilingled to the identification of genetic alterations, which drive and sustain 
tumorigenesis. Activating mutations in the EGFR kinase domain are the mostknown example of 
oncogenic drivers that can be therapeutically targeted by various small-molecule tyrosine kinase 
inhibitors (TKIs)[1]. In this patients’ setting (10-15% of Caucasianpopulation),TKIs of both first 
(erlotinib and gefitinib) and second generation (afatinib) demonstrated significant advantages in terms 
of objective response rate (ORR), progression free survival (PFS) and quality of life (QoL), compared 
with standard platinum-based doublet chemotherapy [2-4]. Recently, another second generation TKI, 
dacomitinib, reporteda statistically significant and clinically meaningful improvement of overall 
survival (OS), compared to gefitinib, butlimited by more significant side effects[5].Despite markedly 
improved outcomes EGFR+ patients eventuallyexperience disease progression, typically within a year 
from treatmentbeginning.The most common mechanism of resistanceis the acquisition of T790M 
mutation within the EGFR kinase domainoccurring in approximately 60% of cases[6].Osimertinib, a 
third-generation EGFR TKI, targets bothEGFR activating and T790M resistance mutations.Based on 
thefavorable results from the phase II and phase III AURA trials [7,8],osimertinibreceived the 
approval for the treatment of EGFR T790M+ NSCLC who progressed during treatment with prior 
TKIs. Itsefficacy has been also reported in the front-line setting: in the FLAURA study the drug 
demonstrated a better PFS (18,9 vs 10,2 months) and ORR (80% vs 76%)with a lower toxicity 
compared to first generation EGFR TKIs[9]. Based on these resultsit has been approvedas a frontline 
treatment for patients with NSCLC who have tumors harboring EGFR mutations. 
 Osimertinib demonstrated a manageable toxicity profile. Most common adverse events 
(AEs)collected in first and further line trials (almost all grade 1 or 2) werediarrhoea, rash, dry skin and 
paronychia.In the FLAURA study,changes in QT interval (the majority of grade 1 or 2)represented the 
most common AEs in the cardiac category (29 patients, 10% in the osimertinib group vs 13 patients, 
5%, in the standard EGFR-TKI group), and implied treatmentdiscontinuation or dosage reduction in 3% 
of patients.Other cardiac events, defined as“ejection fraction decrease” occurred in 8 patients (3%) in 
the osimertinib group and in 3 patients (1%) in the standard EGFR-TKI group and“cardiac 
failure”respectively in 12 patients (4%) and 6 patients (2%),determining dose interruptions in • 1% of 
patients (14).  
 Literature data available do not elucidatea clear causal relationship between cardiotoxicity 
and osimertinib. A consensus about the use of tissue Doppler echocardiography and more 
sophisticated indices (e.g.  global longitudinal strain) for patients without cardiac risk factors is 
lacking; thus, collaboration betweenoncologists and cardiologists is strongly recommended. To 
date,two cases of congestive heart failure have been described only in Asiatic population[10,11].  
 Here, we report five cases of left ventricular dysfunction associated with osimertinib 
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Figure.2 Main parameters collected during echocardiographic examination. A: left ventricular ejection fraction 
(EF)B: indexed left atrium end systolic volume indexed (LAVol/BSA). C: E prime wave on tissue Doppler 
echocardiography. D: E and A wave on trans-mitral pulsed Doppler. E: left ventricular M-mode misures in 
parasternal long axis view 
Case presentations 
PATIENT 1 
A Seventy years-old former smoker men, was diagnosed with advanced stage EGFR-mutated (exon 19 
deletion)lung adenocarcinomain January 2016. He received systemic treatment with gefitinib 250 
mg/die with clinical benefit and radiological stable disease (SD) (byRECIST 1.1 Criteria). Due to 
radiologicaldisease progression and detectionof acquired resistanceT790M mutation on exon 20on a 
tissuebiopsy, the patient started osimertinib 80 mg/daily in November 2016 with a RECIST partial 
response (PR).Any cardiac comorbidityexcept from arterial hypertension was reported. 
 In October 2016 a baseline echocardiographic examshowed a normal left ventricle end-
diastolic volume indexed on body surface area (LvVol D/BSA: 49 ml/m2) and a normal ejection 
fraction (EF: 60%). Left atrium end-systolic volume indexed on BSA (LAVol/BSA: 29 ml/m2) and 
diastolic function (E/A: 0,7; E/E’: 9) were in range. Pulmonary artery pressure (PAPs: 30 mmHg) was 
normal. 
 In January 2017,despite a radiological stability of the disease, the patient progressively 
developed dyspnea. An echocardiographic re-evaluation was performed andrevealed a mild EF 
reduction (45%; -15% from baseline) without left ventricle dilatation, but with a moderate increase of 
left atrium volume (LAVol/BSA: 47 ml/m2). No increase in left ventricle filling pressure was found 
(E/A: 0,5; E/E’: 6) sincethe patient had already started a diuretic therapy (furosemide 50mg twice 
daily);PAPs was 35 mmHG.Adequate medical treatment for cardiac failure was prescribed with low 
dose angiotensin converting enzyme inhibitor (ACEi), ramipril 2,5 mg, bisoprolol 1,25 mg daily and 
osimertinib was discontinued. Three weeks after drug withdrawal,a new echocardiographic 
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examination showed a substantial stability in EF (48%).Symptoms and clinical conditions 
progressively worsened, despite medical treatment and osimertinib withdrawal. To rule out ischemic 
events,a coronary artery CT scan was performed with theonly detection of a critical stenosis of the 
distal right coronary artery, deputed to supply only a small amount of myocardium. A diagnosis of 
osimertinib-induced cardiac toxicity was supposed and the heart failure therapy adjusted. 
Nevertheless,the patient died 10 days later, due to further worsening of cardiac condition. 
 
PATIENT 2 
A Seventy-three years-old never-smokerwomanwas diagnosed in October 2012 with stage IV, EGFR 
mutated (exon 19 deletion)NSCLC.After longradiological disease stability with gefitinib 250 mg/die, 
in March 2016 she developed T790M-induced acquired resistancedetected on tissue specimen 
(together with clinical and radiological lung progression) and started treatment with osimertinib 
80mg/daily. The best radiological response during the 2nd line treatment was stable disease (SD). The 
patient reported a cardiologic history of intermittent left bundle branch block and arterial hypertension. 
The baseline echocardiographic evaluation showed a left ventricle volume at the upper reference limit 
(LvVol D/BSA: 61 ml/m2) with a small increase in indexed left ventricular mass (LVM/BSA: 104 
gr/m2) and a normal systolic function (EF: 62%). A mild (2+/4) mitral valve insufficiency due to 
leaflets fibrosis was present. Left atrium volume (LAVol/BSA: 40 ml/m2) was enlarged, while the 
diastolic function (E/A: 0,7; E/E’: 7) and the pulmonary artery pressure (PAPs: 30 mmHG) were 
normal. Along osimertinib treatment, the patient underwent regular echocardiographic controls every 
three months because of her cardiac history, without any pathological finding. 
 On May 2017, theroutine echocardiography showeda global left ventricular dysfunction (EF 
50%, -12% from baseline). The indexed left atrial and left ventricular volumes remained stable.On the 
contrary, mitral valve insufficiency worsened becoming moderate (3+/4), together with an increase in 
filling pressure (E/A: 0,7, E/E’: 14).  
 Even though the patient was asymptomatic, osimertinibwas suspended for 3 weeks and beta-
blocker (bisoprolol1,25 mg per day) was administered. A new echocardiographic evaluation was 
performed in June 2017 demonstrating a recovery of left ventricle systolic function (EF: 62%). 
Thereafter,osimertinib was restartedat the same dosage. Monthly echocardiographic controlsshowed 
substantial EF stability (62%  63%  58%  61%) and a progressive diastolic function 
improvement (E/A: 0,8  2,2  1  0,6; E/E’: 18  12  9  7). Due to a new reduction in EF 
(61% 54%) and enlargement of left ventricular volume (LvVol D/BSA: 80 ml/mq), without any 
symptoms, in February 2018 the bisoprolol was up-titrated at 3,75 mg per day and osimertinib 
suspended. Subsequent echocardiographic controls demonstrated a small EF improvement (58%) with 
a substantial stability of other parameters. In August 2018 due to a new reduction of EF 




A Forty-seven years-old never-smoker woman was diagnosed in January 2012 with stage IV NSCLC, 
EGFR mutated (exon 19deletion). In April 2016 osimertinib 80 mg/daily was undertaken for lung 
progression togefitinib 250 mg/die (T790M+ detection on tissue). The best radiological response 
during the 2nd line treatment was PR.  
 The baseline echocardiographic evaluation did not show any pathological finding. The first 
echocardiogram, performed six months after osimertinib therapy starts, showed normal dimensions 
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(LAVol/BSA: 27ml/m2; LvVol D/BSA: 54 ml/m2) and function (EF: 64%; E/A: 0,8; E/E’: 6) of the 
left cardiac chambers. Two further echocardiograms, performed at nine and twelve months, confirmed 
these findings. In September 2017,osimertinib was suspended due to asymptomatic LVEF (left 
ventricular ejection fraction) reduction (EF 51%, -13% from baseline).Left chamber volumes and 
diastolic function were not affected from this systolic function reduction. Under cardiologic 
consultation, therapy with bisoprolol (5 mg/day) and perindopril (5 mg/day) was administered, 
resulting in a partial recovery of cardiac function (EF: 56%, + 5%), and osimertinib restarted (October 
2017).Close echocardiographic monitoringcontinued and the patient underwent a full recovery of the 
systolic function (EF: 60%). 
 
PATIENT 4 
A Seventy-oneyears-old never-smoker woman was diagnosed in April 2015 with stage IV 
NSCLCEGFR mutated (exon 19 deletion). Due to lung disease progression to gefitinib 250 mg/die 
and T790M detection on tissue, the patient started osimertinib 80 mg/daily in March 2017. The best 
radiological response during the 2nd line treatment was SD.  
 The baseline echocardiographic evaluation showed normal dimensions (LAVol/BSA: 24 
ml/m2; LvVol D/BSA: 55 ml/m2) and function (EF: 58%; E/A: 0,6; E/E’: 4) of the left cardiac 
chambers. Echocardiograms performed in the following eleven months were stable, except for the 
presence of a mild, stable, circumferential pericardial effusion. In February 2018, osimertinib was 
suspended due to dyspnea associated with a LVEF reduction (EF 45%, -12% from baseline). Left 
ventricle and left atrium volumes were both mild dilated (LAVol/BSA: 42 ml/m2; LVVol D/BSA: 83 
ml/m2).The cardiologic consultation led to the introduction of bisoprolol 2,5 mg/daily, furosemide 
12,5 mg/daily and perindopril 2,5 mg/daily: a subsequent partial recovery of cardiac function (EF: 
54%, + 8%) was observed together with the left chambers volume reduction (LAVol/BSA: 40 ml/m2; 
LVVol D/BSA: 70 ml/m2) andregression of dyspnea. Fifteen days after interruption,osimertinib 
therapy was resumed along with cardiologic therapy prosecution. Clinical and echocardiographic 
controls showed a stabilization of the cardiac function. 
 
PATIENT 5 
A Eighty years-old never-smokerwoman affectedby stage IV EGFR mutated (exon 19 
deletion)NSCLC(diagnosis in October 2014) started a first line therapy with gefitinib 250 mg/die; in 
January 2017 because of lung progression and detection of T790M mutation on plasma, the treatment 
withosimertinib 80 mg/daily was started.The best radiological response during the 2nd line treatment 
was SD. Arterial hypertension was the only patient’s comorbidity. The baseline echocardiographic 
evaluation did not show any pathological findings. The first echocardiogram performed two months 
later showed a mild enlargement of the left atrium (LAVol/BSA: 35 ml/m2), a mild increase in 
indexed left ventricular mass (LVM/BSA: 97 gr/m2)and normal dimensions (LvVol D/BSA: 61 ml/m2) 
and function (EF: 62%; E/A: 0,5; E/E’: 5) of the left ventricle.After eleven months of therapy the 
patient developed an asymptomatic reduction of the systolic function (EF: 43%, -19% from baseline) 
and an increase in left ventricle mass and left atrial volume (LVM/BSA: 104 gr/m2; LAVol/BSA: 50 
ml/m2). Osimertinib was temporarily suspended and enalapril therapy titrated from 2,5 mg to 5 mg per 
day. Three weeks after osimertinibdiscontinuation, a new echocardiogram showed a systolic function 
improvement (EF 43%  55%) and stabilization of left chambers volumes, thuswe reintroduced the 
target therapy. In April 2018 themonthly cardiac follow updemonstrated further reductionin systolic 
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function (EF 52%). We reducedosimertinib dose at 40mg/die with a stable echocardiographic 
monitoring until June 2018 when the treatment was permanently discontinued for progressive disease. 
Discussion 
American and Europeanosimertinib labels both carry warnings of cardiomyopathy and changes in 
cardiac contractility during treatmentand recommendcardiac monitoring (assessment of LVEF at 
baseline and during treatment) in patients with cardiac risk factors or with conditions that can affect 
LVEF. A dose modification/discontinuation is suggested in case of decrease in LVEF of 10% from 
baseline and below 50%, or in case of symptomatic congestive heart failure[12]. A causal 
underpinning of relationship between osimertinib and cardiaccomplications remains weak. Actually, 
many of the pathways responsible for proliferation in malignant cells also play crucialroles in 
cardiomyocytes biology, such as survival and electrical and contractile function. Implications of 
tyrosine kinases in cardiomyocyte survival signaling were first evaluated with trastuzumab (a 
monoclonal antibody against human epidermal growth factor receptor 2). Another EGFR family 
member, ERBB1, inhibited by osimertinib, may also be involved in cardio protectionand myocyte 
survival, based on common downstream pathways to the EGFR family receptors[13]. Our case series 
confirms the potential risk of osimertinib-related cardiac toxicity and allows some hypotheses:  
1. Cardiac toxicity seems only partially related to previous cardiac conditions or high cardiovascular 
profile risk. With the exception of one patient,bearinga moderate valvular disease, none of our patients 
had previous cardiovascular diseases and their cardiovascular risk profile was low, as in the other two 
clinical cases already reported [10, 11]. 
2. Osimertinib cardiac toxicity seems to be more common in female (as in the two previous case 
reports and in four of our five patients). We can partly explainthis observation with the highest 
prevalence of NSCLC with EGFR mutation in females.However, a gender difference influencecould 
not be excluded [14]. 
3. Osimertinib cardiotoxicity seems to be reversible and, for this reason, is more likely to be a type 2 
cardiotoxicity, like the trastuzumab-related one. Similarly to previous observations made on 
trastuzumab treated patients, we did not find a worsening of diastolic function, but only a systolic 
function impairment. Then, type 2 cardiotoxicity could have a different behavior than type 1, in which 
the systolic function is affected after the development of a diastolic dysfunction[15].We underline, 
however, the very small sample size upon which this hypothesis is based.  
4. The development of protocols including global longitudinal strain (GLS) and cardiac magnetic 
resonance is, in our opinion, of paramount importance to identify patients who could benefit of a 
dosage reduction or a transitory interruption of osimertinib in order to prevent the progression to an 
overt cardiac dysfunction. 
5. The use of beta-blockers and ACEi seems to have a sort of cardio-protective role in patients who 
develop a reduction of systolic function[16]. This topic needs further investigationsin order to 
determine whether continuingosimertinib in association with a cardioprotective therapy in patients 
who develop an initial cardiac dysfunctionis safe or not.  
Conclusions 
In this scenario of paramount efficacy and a global favorable safety profile ofosimertinib, a rising 
awareness of cardiovascular complications can help the minimization of adverse toxicities. A fully 
understanding of the risk factors plays a critical role. Prospective data investigating the role of routine 
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high sensitivity troponin evaluation, brain natriuretic peptide(BNP), tissue Doppler and speckle 
tracking echocardiography could representtools to early identify cardiac toxicity. With the expanding 
use of osimertinib, even in front-line setting, we should keep in mind that strategies to prevent or 
mitigate cardiovascular damage from cancer therapies are important to provide the best care. Cancer 
treatmentsare multifaceted and need not only the well-known coordination among oncologists, 
surgeons and radiation oncologists but also a larger multidisciplinary approach in which every issues, 
including potential toxic side effects,are carefully evaluated. 
Consent 
The patients/families have given their informed consent for the case series to be published. 
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